Leader Research | Hamilton, Canada

Research site

(Unclaimed)

Location

928 Barton Street East, Hamilton, Ontario, Canada

Site insights

Top conditions

Top treatments

Rocatinlimab

Upadacitinib

Dupilumab

RPT193

Ruxolitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 10 total trials

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (ROCKET-Ignite)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

Drug: Placebo

Locations recently updated

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

Locations recently updated

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling

Atopic Dermatitis

Drug: Rocatinlimab

Other: Placebo

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Dupilumab